Protective HA Factors
Protective Headache Factors for Migraineurs and Postconcussive Headache Patients: Are Behavioral Strategies Effective? A Naturalistic Study
調査の概要
詳細な説明
Patients will be given a link to audio files on dropbox which they can download onto their smartphone. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times a week. Patients will record their headache frequency and intensity, in addition to other symptoms, and the frequency of practicing the behavioral therapy using Curelator Headache. ™ Curelator Inc. (Cambridge USA) has developed a proprietary, non-pharmaceutical, digital platform, called Curelator Headache,™ to collect daily data, identify trigger-attack associations and propose 'tests' of trigger modification.
The Curelator approach requires high quality data from the individual, entered on a daily basis. Compliance is expected to be enhanced because the study if being offered by the individual's healthcare provider.
This a pilot study of an initial 90 days use of a digital platform to identify potential migraine protective factors (Curelator Headache™) in subjects with physician-diagnosed episodic or chronic migraine or post-concussive headache. Subjects are recruited to Curelator Headache use by a physician and enter data each day. The baseline period (90 days) is followed by a test period (90 days) during which, under Curelator guidance, subjects make one or more modifications to their behaviors based on the data from the 90 day period.
The study will include up to 100 patients with chronic or episodic migraine and 75 patients with postconcussive headache. At clinics, investigators will offer participation to consecutive migraine patients with 6-20 headache days a month and to consecutive concussion patients complaining of headache more than 1 month post concussive event.
研究の種類
段階
- 適用できない
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10016
- New York University Langone Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female reporting at least 6 month history of episodic or chronic migraine with 6-20 headache days a month
- Age: 18-65 years
- Age of onset of migraine was <age 50
- Able to give informed consent/assent
- Sufficiently fluent in English to be able to use the English language version of Curelator Headache (no translations available).
- Has ownership of or reliable access to iPhone or (mini) iPad running iOS 7 or higher
- Able to give written informed consent (adults), or, for adolescents, has a parent/caregiver who can give informed consent and adolescent is able to give assent.
- Willing to use Curelator Headache for at least 3 months and to comply with study procedures.
- In the Investigator's opinion, there is no reason to believe that Curelator Headache use would pose any risk to the patient.
Exclusion Criteria:
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：非ランダム化
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Episodic Migraine group
100 patients with chronic or episodic migraine
|
Patients will be given a link to download audio files.
They consist of breathing techniques, imaging, progressive relaxation, and more.
Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week.
Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
|
|
実験的：Chronic Migraine Group
100 patients with chronic or episodic migraine
|
Patients will be given a link to download audio files.
They consist of breathing techniques, imaging, progressive relaxation, and more.
Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week.
Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
|
|
実験的：Post concussive Headache Group
75 patients
|
Patients will be given a link to download audio files.
They consist of breathing techniques, imaging, progressive relaxation, and more.
Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week.
Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of completers (assessment of adherence)
時間枠：90 Days
|
90 Days
|
|
|
Number of days with migraine and other headache
時間枠：90 Days
|
90 Days
|
|
|
Number of migraine headaches
時間枠：90 Days
|
90 Days
|
|
|
Number of significant trigger/warning sign - migraine attack associations
時間枠：90 Days
|
This will be analyzed by means of univariate Cox Proportional Hazards (PH) models.
At the end of the study period (Day 90) significant trigger factors (HR/RR>1 and p-value ≤ 0.05) will be identified for each individual: the number and percentage of subjects with at least one significant relationship between a trigger and occurrence of migraine attacks and the number of trigger-migraine attack significant relationships per individual will be estimated by means of descriptive statistics.
|
90 Days
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Mia Minen, MD、NYU Langone Health
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
脳震盪後頭痛の臨床試験
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd完了原発性骨髄線維症 (PMF) | 真性骨髄線維症（Post-PV MF） | 本態性血小板血症後骨髄線維症(Post-ET MF)中国
-
Kartos Therapeutics, Inc.募集原発性骨髄線維症 (PMF) | 真性多血症後の MF (Post-PV-MF) | 本態性血小板血症後の MF (Post-ET-MF)アメリカ, 大韓民国, ドイツ, オーストラリア, ハンガリー, フランス, スペイン, イタリア, 台湾, タイ, ブラジル, ポーランド, 七面鳥, イスラエル, ポルトガル, ルーマニア, アルゼンチン, ブルガリア, カナダ, クロアチア, チェコ, リトアニア, メキシコ, フィリピン, イギリス, 香港, ロシア連邦, ギリシャ
-
GlaxoSmithKline積極的、募集していない新生物 | 原発性骨髄線維症 (PMF) | 多血症後 真性骨髄線維症 (Post-PV MF) | 本態性血小板血症後骨髄線維症 (Post-ET MF)アメリカ, ハンガリー, イスラエル, スペイン, 台湾, フランス, オーストラリア, ドイツ, ベルギー, カナダ, シンガポール, 大韓民国, イギリス, デンマーク, オーストリア, ルーマニア, イタリア, ブルガリア, ポーランド, オランダ
-
Samus Therapeutics, Inc.終了しました原発性骨髄線維症 (PMF) | 多血症後の真性骨髄線維症 (Post-PV MF) | 本態性血小板血症後骨髄線維症（ET MF後）アメリカ
-
Sierra Oncology, Inc.完了原発性骨髄線維症 (PMF) | 本態性血小板血症後骨髄線維症 (Post-ET MF) | 真性多血症後（PV後）アメリカ, カナダ, フランス, イタリア, ドイツ, スペイン, イスラエル, イギリス
Audio Filesの臨床試験
-
Brooke Army Medical CenterUniversity of Colorado, Denver積極的、募集していない
-
Damascus University完了